In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 2 Post-assessment*** Survey

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials?

MD/DO

Nurse

PharmD

Other (please specify)

Question Title

* 2. What is your area of specialty?

Hematology

Oncology

Other (please specify)

Question Title

* 3. How many years have you been in practice?

1-10

11-20

>21

Question Title

* 4. Please select the option that best describes your practice setting:

Academic medical center

Community hospital or medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 5. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with ALL in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 7. Incorporation of blinatumomab into the treatment strategy for front-line therapy of high risk-disease in adult patients with Philadelphia chromosome negative ALL and in children and adolescents/young adults with low-risk, first relapse ALL demonstrated which of the following?

Cytokine release syndrome in > 50% of patients

Acceptable safety

Improvement in disease-free survival

Improvement in overall survival

Question Title

* 8. WA is a 12-year-old girl diagnosed with B-cell ALL 3 years ago with a first isolated marrow relapse after completing maintenance therapy. She is MRD negative after reinduction on AALL1331. Which of the following should be incorporated into management of WA?

Blinatumomab

Inotuzumab

Tisagenlecleucel

Allogeneic stem cell transplant

Question Title

* 9. Compared with chemotherapy as post-reinduction therapy in low-risk, first relapse of B-cell ALL in children and adolescents/young adults, which of the following best reflects outcomes associated with the incorporation of blinatumomab?

Higher rates of febrile neutropenia, infection and anemia

Improved DFS / OS in patients with isolated extramedullary relapse

Improved DFS / OS in patients bone marrow ± extramedullary relapse

Improved DFS / OS in all patients

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

Question Title

* 10. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 11. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice?

Recognize the role of asparaginase, pegaspargase, and alaspargase pegol in the front-line treatment of ALL

Utilize therapeutic drug monitoring to help discern between different treatment reactions

Recall management strategies for asparaginase toxicity

Determine when rechallenge with asparaginase is possible

Question Title

* 13. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 14. After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults	Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults Strongly agree	Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults Agree	Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults Neutral	Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults Disagree	Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults Strongly disagree
Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients	Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients Strongly agree	Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients Agree	Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients Neutral	Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients Disagree	Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients Strongly disagree

Question Title

* 15. The following faculty presenter effectively presented the material:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Ryan D. Cassaday, MD	Ryan D. Cassaday, MD Strongly agree	Ryan D. Cassaday, MD Agree	Ryan D. Cassaday, MD Neutral	Ryan D. Cassaday, MD Disagree	Ryan D. Cassaday, MD Strongly disagree
Luke Maese, DO	Luke Maese, DO Strongly agree	Luke Maese, DO Agree	Luke Maese, DO Neutral	Luke Maese, DO Disagree	Luke Maese, DO Strongly disagree

Question Title

* 16. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

Question Title

* 20. Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

First & Last Name

Degree/Credentials

ZIP/Postal Code

Country

Email Address

Question Title

* 21. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 2 Post-assessment***

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your area of specialty?

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with ALL in your practice?

Question Title

* 7. Incorporation of blinatumomab into the treatment strategy for front-line therapy of high risk-disease in adult patients with Philadelphia chromosome negative ALL and in children and adolescents/young adults with low-risk, first relapse ALL demonstrated which of the following?

Question Title

* 8. WA is a 12-year-old girl diagnosed with B-cell ALL 3 years ago with a first isolated marrow relapse after completing maintenance therapy. She is MRD negative after reinduction on AALL1331. Which of the following should be incorporated into management of WA?

Question Title

* 9. Compared with chemotherapy as post-reinduction therapy in low-risk, first relapse of B-cell ALL in children and adolescents/young adults, which of the following best reflects outcomes associated with the incorporation of blinatumomab?

Question Title

* 10. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 11. Which of the following best describes the impact of this activity on your performance?

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice?

Question Title

* 13. What barriers do you see to making changes in your practice?

Question Title

* 14. After participating in today’s activity, I am now better able to:

Question Title

* 15. The following faculty presenter effectively presented the material:

Question Title

* 16. The content presented:

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

Question Title

* 20. Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

Question Title

* 21. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 CreditTM.

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
Poster 2 Post-assessment

* 21. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.